drugset / Trial / NCT05804864
A Study of KM501 in Patients With Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
A single-arm, open, multicenter Phase I study to evaluate the safety, tolerability, pharmacokinetic profile, and efficacy of the KM501 double-antibody ADC in subjects with advanced solid tumors that express, amplify, or mutate HER2
Timeline
- Start
- 2023-04
- Primary completion
- 2026-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KM501 | Unknown | 0.1 mg/kg | — |
| Subject | KM501 | Unknown | 0.3 mg/kg | — |
| Subject | KM501 | Unknown | 0.6 mg/kg | — |
| Subject | KM501 | Unknown | 1.2 mg/kg | — |
| Subject | KM501 | Unknown | 1.8 mg/kg | — |
| Subject | KM501 | Unknown | 2.4 mg/kg | — |